MosmannTR, CoffmanRL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989; 7:145–173.
2.
NeillDR, WongSH, BellosiA, et al.Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010; 464(7293):1367–1370.
3.
GandhiNA, BennettBL, GrahamNM, et al.Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016; 15(1):35–50.
4.
Technology Innovative Technologies Lead to Medical Progress. Secondary Technology Innovative Technologies Lead to Medical Progress 2023. Available at https://www.regeneron.com/science/technology Accessed January19, 2024.
5.
BeckLA, ThaciD, HamiltonJD, et al.Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014; 371(2):130–139.
6.
SimpsonEL, BieberT, Guttman-YasskyE, et al.Two Phase 3 Trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016; 375(24):2335–2348.
7.
BusseWW, MasperoJF, RabeKF, et al.Liberty Asthma QUEST: Phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther. 2018; 35(5):737–748.
8.
RabeKF, NairP, BrusselleG, et al.Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018; 378(26):2475–2485.
9.
WenzelS, CastroM, CorrenJ, et al.Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016; 388(10039):31–44.
10.
PetersAT, WagenmannM, BernsteinJA, et al.Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis. Allergy Asthma Proc. 2023; 44(4):265–274.
11.
DellonES, RothenbergME, CollinsMH, et al.Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022; 387(25):2317–2330.
12.
YosipovitchG, MollanazarN, StanderS, et al.Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023; 29(5):1180–1190.
